Evaluate the safety and immunogenicity of ALVAC-HIV vCP205 and HIV-1 SF rgp120. The vaccine is to be given to healthy HIV-1 unifected adult volunteers by alternative foutes of delivery to assess th edevelopment of mucosal immunity, followed by boosting with HIV-1 SF-2 rgp 120 delivered by the IM route. We are nearing recruitment and enrollment for this study. WE are focusing most of our efforts on follow up.
Showing the most recent 10 out of 515 publications